Back to Search
Start Over
Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.
- Source :
-
Frontiers in oncology [Front Oncol] 2024 May 23; Vol. 14, pp. 1379013. Date of Electronic Publication: 2024 May 23 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Background: Olfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the recurrent or metastatic (R/M) ONB population remains unclear.<br />Methods: We retrospectively evaluated 11 patients with R/M ONB who received any systemic chemotherapy at two Japanese institutions (National Cancer Center Hospital East and Kyushu Medical Center) between January 2002 and March 2022 and analyzed outcomes by use of anti-PD-1 antibody (nivolumab or pembrolizumab) monotherapy.<br />Results: Of the 11 patients, 6 received ICI (ICI-containing treatment group) and the remaining 5 were treated with systemic therapy but not including ICI (ICI-non-containing treatment group). Overall survival (OS) was significantly longer in the ICI-containing group (median OS: not reached vs . 6.4 months, log-rank p -value: 0.035). The fraction of ICI systemic therapy in the entire treatment period of this group reached 85.9%. Four patients (66.7%) in the ICI-containing treatment group experienced immune-related adverse events (irAE), with grades of 1/2. No irAE of grade 3 or more was seen, and no patient required interruption or discontinuation of treatment due to toxicity.<br />Conclusion: ICI monotherapy appears to be effective and to contribute to prolonged survival in R/M ONB.<br />Competing Interests: MT reports grants and personal fees from Ono Pharmaceutical and Bayer; personal fees from MSD, BMS, Merck Biopharma, Pfizer, Rakuten Medical, Lilly, Boehringer Ingelheim, Eisai, Chugai Pharmaceutical, Daiichi-Sankyo, Janssen Pharmaceutical, Genmab, Astra Zeneca, Abbvie and Astellas, outside the submitted work. SO reports personal fees from Ono Pharmaceutical, MSD, BMS, Merck Biopharma. TE reports personal fees from Ono Pharmaceutical, Bayer, MSD, and Merck Biopharma outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Hoshi, Enokida, Tamura, Nakashima, Okano, Fujisawa, Sato, Wada, Tanaka, Takeshita, Tanaka, Onaga, Kishida, Uryu, Sakashita, Asakage and Tahara.)
Details
- Language :
- English
- ISSN :
- 2234-943X
- Volume :
- 14
- Database :
- MEDLINE
- Journal :
- Frontiers in oncology
- Publication Type :
- Academic Journal
- Accession number :
- 38846982
- Full Text :
- https://doi.org/10.3389/fonc.2024.1379013